Wedbush Research Analysts Boost Earnings Estimates for TCRX

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Analysts at Wedbush upped their FY2024 earnings per share estimates for shares of TScan Therapeutics in a research report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($1.09) per share for the year, up from their prior forecast of ($1.13). Wedbush has a "Outperform" rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.17) per share. Wedbush also issued estimates for TScan Therapeutics' Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.96) EPS and FY2027 earnings at ($0.76) EPS.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $0.54 million during the quarter, compared to analysts' expectations of $1.55 million.

Other equities analysts have also issued reports about the company. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of TScan Therapeutics in a report on Friday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $12.00.

TScan Therapeutics Trading Down 8.5 %

NASDAQ:TCRX traded down $0.41 during trading hours on Friday, hitting $4.41. The stock had a trading volume of 244,070 shares, compared to its average volume of 246,912. The business's 50 day moving average is $5.33 and its 200-day moving average is $6.51. The company has a market cap of $233.62 million, a price-to-earnings ratio of -4.14 and a beta of 0.79. TScan Therapeutics has a one year low of $3.73 and a one year high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.77 and a current ratio of 9.56.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, insider Zoran Zdraveski sold 164,686 shares of the business's stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the transaction, the insider now directly owns 4,716 shares of the company's stock, valued at approximately $27,258.48. The trade was a 97.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barbara Klencke purchased 5,000 shares of the firm's stock in a transaction on Monday, September 23rd. The stock was bought at an average cost of $5.29 per share, with a total value of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares of the company's stock, valued at approximately $238,050. This represents a 12.50 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 15,000 shares of company stock valued at $82,550 in the last ninety days. 2.76% of the stock is currently owned by company insiders.

Institutional Trading of TScan Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TCRX. Tocqueville Asset Management L.P. purchased a new stake in TScan Therapeutics during the first quarter worth about $1,685,000. Bank of Montreal Can bought a new position in TScan Therapeutics in the 2nd quarter valued at $749,000. Bank of New York Mellon Corp purchased a new position in TScan Therapeutics during the second quarter worth about $682,000. Great Point Partners LLC bought a new position in shares of TScan Therapeutics in the second quarter worth approximately $5,504,000. Finally, Marshall Wace LLP raised its position in shares of TScan Therapeutics by 60.8% during the 2nd quarter. Marshall Wace LLP now owns 307,487 shares of the company's stock valued at $1,799,000 after buying an additional 116,316 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.